Expression patterns of LncRNA-GAS5 and its target APOBEC3C gene through miR-103 in breast cancer patients

Abstract

Early diagnosis of breast cancer can increase the survivability of the patients and the patient’s quality of life. There is growing evidence demonstrating the active role of LncRNA-GAS5 and miR-103 in cancer biology. APOBEC enzymes are important players in immunity and may contribute to carcinogenesis. Mutation and expression alteration in the APOBEC gene family was found to have a strong correlation with breast cancer risk. This study aimed to evaluate the expression level of lncRNA-GAS5 and its target APOBEC3C in women with breast cancer through expression evaluation of miR-103. Moreover, the interaction between lncRNA-GAS5 and miR-103 was studied. In the present study, forty paired tumor and normal samples classified based on breast cancer subtypes and clinical features of patients were analyzed using gene expression studies. Immunohistochemical analysis of the gene products was performed to classify tumors. The RNA samples were extracted from breast tissue. Real-time PCR was conducted for APOBEC3C and Lnc-RNA GAS5 expression. In addition, miR-103a miScript Primer Assay was utilized for the expression of miR-103-5p. It was revealed that the expression level of APOBEC3C and lncRNA-GAS5 were significantly down-regulated; however, the miRNA-103 expression level was significantly up-regulated. GAS5 expression was positively correlated with APOBEC3C expression and negatively correlated with miR-103 expression. In conclusion, we observed down-regulation of APOBEC3C and LncRNA-GAS5 and up-regulation of miRNA 103 in breast cancer patients. The expression of GAS5 may provide a new potential treatment target for breast cancer. To clarify the role of these molecules in the cellular signaling pathways, further studies are required.

Detection of TP53 gene mutation in blood of breast cancer patients based on circulating tumor DNA and its application in prognosis

“…The occurrence and development mechanism of breast cancer is complex, and its process involves multiple genes, multiple steps, and multiple internal and external factors such as immunity, environment and genetics (12). Research shows that the disordered cell signal transduction pathway plays a very important role in the occurrence and development of breast cancer, and the mutation of related genes plays an important role in the progression, pathological classification and prognosis of breast cancer (13).…”

Silencing of long non-coding RNA SDCBP2-AS1/microRNA-656-3p/CRIM1 axis promotes ferroptosis of lung cancer cells

“…LncRNAs participate in competitive regulation, acting as sponges for miRNAs to regulate gene expression (19). MiR-656-3p is a tumor suppressor in cancers, such as nasopharyngeal carcinoma (20), liver cancer (21), and colorectal cancer (22).…”

Serum long non-coding RNAs as potential noninvasive biomarkers for glioblastoma diagnosis, prognosis, and chemoresistance

“…LncRNA GAS5 gene is located on chromosome 1q12.1 [60]. LncRNA GAS5 is considered an antioncogenic lncRNA and is downregulated in many tumors including ovarian and breast cancers, non-small cell lung cancers, large B-cell lymphoma, and gastric and laryngeal cancers [60][61][62][63][64][65]. In contrast, lncRNA GAS5 acts as an oncogenic lncRNA and is overexpressed in other tumors such as hepatocellular carcinoma and cholangiocarcinoma [66,67].…”